91̽»¨

University 91̽»¨
  2. About
  3. Find staff
  4. Khalil Helou

Khalil Helou

Researcher

Department of Oncology
Telephone
+46 31-786 67 46
Mail
khalil.helou@oncology.gu.se
Fax
+46 31-41 32 90
Visiting address
Medicinaregatan 1G
41390 Göteborg
Postal address
Cancercentrum Box 425
405 30 Göteborg

About Khalil Helou

Khalil Helou received PhD in Molecular Genetics at the University 91̽»¨, Sweden in 2000. After a postdoc period at the NIH / NCI Bethesda in the United States, he was appointed a position in 2003 as group leader responsible for breast cancer research at the Department of Oncology at Sahlgrenska Hospital in Gothenburg. As a researcher, he gained extensive experience about how to manage a research team and supervise undergraduate and PhD students. He is currently supervising two PhD students, one postdoc and co-supervising six PhD students, and he was the main supervisor for six PhD students and co-supervisor for eight PhD students, resulting in six and eight doctoral dissertations, respectively. His role as supervisor could be summarized by: (1) coaching the students and not leading them, (2) introducing them to the area of research, (3) introducing them to other researchers, clinicians, etc., (4) developing competence, (5) selecting relevant PhD courses and conferences and (6) applying for research grants, etc. In addition to holding several lectures for PhD courses, he was the course coordinator and lecturer for three PhD courses. My publication list extends to about 114 scientific articles in international peer-reviewed journals. In addition to serving as a journal referee for several international peer-reviewed journals, he is the Associate Editor of the BMC Cancer journal and was a committee member of the permanent PhD examining board at Sahlgrenska Academy. He was assigned several scientific advisory functions such as opponent, examination board member for more than 60 doctoral dissertations, employments and Associate Professorships for other researchers. He is currently the vice prefect of the Council for PhD education at the Institute of Clinical 91̽»¨s and the Council for PhD courses at Sahlgrenska Academy. In 2019, he was appointed as the Joint Director of PhD studies at Sahlgrenska Academy. I have four children, Mikael 31 years old (MD resident in Psychiatry), Daniel 27 years old (MD resident in Internal medicine), Gabriella 18 years old, and Alexandra 15 years old.

Research area: Novel prognostic and predictive biomarkers for ovarian cancer treatment decisions: Translational research

Research environment: The research is conducted at Sahlgrenska Center for Cancer Research which is a biomedical research center consisting of several research groups, created by joint efforts of several institutes at Sahlgrenska Academy at University 91̽»¨, which have expanded and integrated their research activities on a common campus. In addition, we have access to animal facilities at the Laboratory for Experimental Biomedicine (EBM).The group comprises several researcher Khali Helou (genetist), Pernilla Dahm Kähler (gynecologist), Per Karlsson and Lars Ny (oncologists), Anikó Kovács (pathologist) Toshima Parris (molecular biologist), PhD students (Lucas Werner, Hugo Swenson, Elisabeth Werner Rönnerman, Luaay Aziz, Ella Ittner, and Maxim Olsson), technical assistants (Prajakta Hetaker). Other contributing researchers oncologist (Zakaria Einbeigi), biostatistician (Szilard Nemes), Statistician (Erik Holmberg). Together with our collaborators, we have a broad knowledge and expertise in the clinic and lab.

Project: Ovarian cancer is the second most common and lethal gynecologic malignancy in the western world. After initial successful treatment, approximately 80% of all ovarian cancer patients develop recurrence within five years after initial diagnosis. Currently, there is no effective way of stratifying patients based on clinical outcome or benefit of adjuvant treatment after surgery. Therefore, many patients would profit from a complement to established prognostic markers. We hypothesize that for most patients, the genetic makeup of the primary tumor can predict aggressive tumor features that determine whether relapse may occur.

To test this hypothesis, we will analyze the genetic signatures of a cohort of ovarian carcinomas in order to identify potential novel biomarkers that can better classify ovarian tumors and predict aggressive tumor behavior. Our specific objectives are to: (1) identify cancer driver genes associated with ovarian cancer-specific survival and different OC histotypes, (2) determine whether altered protein levels of the candidate biomarkers are associated with ovarian cancer-specific survival and different ovarian cancer histotypes, and (3) define the tumorigenic and therapeutic potential of candidate biomarkers using patient-derived cancer cells and mouse models.

The proposed project will potentially improve the molecular classification of ovarian carcinomas representing different histotypes. Importantly, our work will shed light on the role of the identified biomarkers in tumor behavior and ultimately may provide valuable information to guide the decision-making process for ovarian cancer treatment.

Supervision

Current PhD students under my supervision

  1. Lucas Werner
  2. Hugo Swenson
  3. Luaay Aziz, MD, MB ChB
  4. Elisabeth Werner Rönnerman, MD

Current PhD students under my co-supervision

  1. Ella Ittner
  2. Anna Fäldt Beding
  3. Nishte Dello
  4. Anja Schroff
  5. Maxim Olsson
  6. Amalia Landén
  7. Amy Hardy
  8. Ingun Ståhl
  9. Hana Bakr

Former PhD students under my supervision

  1. Elin Karlsson: Novel biomarkers predicting long-term survival in breast cancer, 2009
  2. Szilárd Nemes: Integrative genomic and survival analysis of breast tumors 2012
  3. Emman Shubbar: Analysis of Novel Biomarkers for Unfavorable Breast Cancer Prognosis 2012
  4. Toshima Parris: High-risk breast cancer. From biology to personalized therapeutic strategies 2014
  5. Jana Biermann: Tumour evolution and novel biomarkers in breast cancer 2019
  6. Hanna Engqvist: Novel biomarkers associated with histotype and clinical outcome in early-stage ovarian carcinoma 2020

Former PhD students under my co-supervision

  1. Anna Danielsson, PhD 2005
  2. Tatjana Adamovic, PhD 2006
  3. Ahmad Hamta, PhD 2006
  4. Emil Schuler, PhD 2015
  5. Nils Rudqvist, PhD 2015
  6. Britta Langen, PhD 2015
  7. Johan Spetz, PhD 2017
  8. Viktor Sandbloms, PhD 2019
  9. Malin Larsson, PhD 2021
  10. Jenny Nyqvist. PhD 2021
  11. Charlotte Andersson PhD 2022
  12. Axel Stenmark Tullberg PhD 2022
  13. Arman Romiani PhD 2023
  14. Peter Larsson PhD 2023
  15. Mikael Elvborn2023

Former postdocs under my supervision

  1. Irina Corin 2005
  2. Anna Danielsson
  3. Toshima Parris (2016-2017)

Publications

  • 114 Peer reviewed original articles
  • 6 manuscripts (2 under review)

Involvment in scientific journals

  • Editorial board member of the BMC Cancer
  • Editorial board member of the Biomedicines
  • Reviewer for a substantial number of scientific journals

Grants

  • A novel targeted treatment against ovarian cancer Eurostars (Vinnova)
  • Novel prognostic and predictive biomarkers for treatment decisions in breast and ovarian cancer Swedish Cancer Society
  • Novel prognostic and predictive biomarkers for ovarian cancer treatment decisions Swedish Cancer Society
  • Novel prognostic and predictive biomarkers for ovarian cancer treatment decisions Jk Cancer Research Foundation
  • Prognostiska biomarkörer som nya behandlingsredskap mot aggressiv äggstockscancer ALF-projektmedel
  • Novel prognostic and predictive biomarkers for ovarian cancer treatment decisions Project-linked doctoral project Sahlgrenska Academy
  • Clinical significance of the Lemur Tyrosine Kinase 3 as a potential target for ovarian cancer treatment Swedish Cancer Society

ORCID